There will be two sessions of "Decon Training for Today’s Real World Responses".
Recently, a second field was added to the NYS EMS Collaborative Protocol App for ECMC. Please select carefully:
ECMC Trauma Program will be hosting Trauma Tuesday on
Tuesday, February 19, 2019 at 2:00 p.m.
Join them as they present and discuss 3-4 blinded trauma cases. A panel of physicians and nurses will discuss opportunities for improvement and positive aspects of the cases from pre-hospital through discharge. The EMS crews are encouraged to participate and offer insight so we can all learn from each other. Join them in person or via the following link: https://global.gotomeeting.com/join/359413357
Annually the New York State Department of Health, Bureau of Emergency Medical Services, presents awards in several categories. These awards are presented at the New York State EMS Conference, Vital Signs each year.
Applications for individual or team achievement awards shall be based on a pattern of activities that have culminated in a significant improvement of Emergency Medical Services in the community. Applications for individual or team heroism shall be based on a single unusual event that was beyond ordinary duty. All nominees, in both achievement and heroism categories, must be affiliated with a NYS EMS agency. Agencies must possess a current and valid ID code as an ambulance service or first response service. Individuals must be credentialed to practice within NY State.
All applications for the New York State EMS Annual Awards must be submitted to the Regional Council using the application on the website. If you would like to make a nomination for an achievement award, please submit your application to the Southwestern Regional EMS Council by Friday, March 29, 2019 to be reviewed at the April 3, 2019 SWREMS meeting in order to be submitted to NYSDOH BEMS by the May 1, 2019 deadline.
Please click here for more information.
Please click here for the application.
Applications can be sent to:
Southwestern Regional EMS Council c/o STHCS
150 North Union Street
Olean, NY 14760
Please see the below links on a voluntary recall of LifePack 15 model Monitor/Defibrillator. If you have one of these units, please reach out to Stryker to get this resolved.
Please click here for the recall notice.
Please click here for information about this notice from Stryker.
Here is a link to the State Register: Rule Making Activities. The notice of adoption appears on page 13.
Here is a link to the adopted regulation on the DOH website: Emergency Medical Services Initial Certification Eligibility Requirements
Jamestown Community College Center for Continuing Education will be holding EMT-B Original and Refresher Courses in the Spring 2019 semester starting in January. Please see below for course announcements.
Please click here for the EMT Original Course Announcement.
Please click here for the EMT Refresher Course Announcement.
If you have any questions please contact JCC at:
Jamestown Community College
Center for Continuing Education (EMT Original Program)
525 Falconer Street
Jamestown, NY 14701
SafeTALK is a half-day alertness training that prepares anyone 15 or older, regardless of prior experience or training, to become a suicide-alert helper. Most people with thoughts of suicide don’t truly want to die, but are struggling with the pain in their lives. Through their words and actions, they invite help to stay alive. SafeTALK-trained helpers can recognize these invitations and take action by connecting them with life-saving intervention resources, such as caregivers trained in ASIST.
This event will be at Southern Tier Health Care System on Saturday, Dec. 15 from 9 a.m. to noon and is sponsored by STHCS and Ardent Solutions of Wellsville.
Unlike yesterday’s epinephrine auto injector email I sent regarding precautionary handling instructions, this one IS a recall from Boundtree which is the manufacturer of CURAPLEX EPI-SAFE KIT (syringe epi).
Please click here for the notice.
FDA alerts patients and health care professionals that some EpiPen auto-injectors may not readily slide out of carrier tube
This is NOT a recall.
FDA is alerting patients, caregivers and health care professionals that the labels attached to some EpiPen 0.3mg and EpiPen Jr 0.15mg auto-injectors, and the authorized generic versions, may block access to the auto-injector and prevent the ability to easily access the product.
In a letter to health care professionals from Pfizer, the manufacturer of the Mylan EpiPen, the label sticker on the auto-injector unit may have been improperly applied, causing resistance when removing it from the carrier tube. The carrier tube is the immediate package in which the auto-injector is contained. In some cases, the patient or caregiver may not be able to quickly remove the epinephrine auto-injector from the carrier tube.
The auto-injector device and the epinephrine it delivers are not affected by this issue and can be used as prescribed. It is vital for lifesaving products to work as designed in an emergency situation, and patients and caregivers should inspect their epinephrine auto-injector prior to needing it to ensure they can quickly access the product.
The letter also describes how to inspect potentially affected products and explains that patients should contact Mylan Customer Relations at 800-796-9526 if an auto-injector does not slide out easily from the carrier tube ORthe label is not fully adhered to the auto-injector. Pharmacists should inspect the products before dispensing them to patients to ensure quick access to the auto-injector and should not dispense any product which does not easily slide out of its carrier tube.
FDA is not aware of any adverse event reports associated with improperly applied EpiPen or EpiPen Jr auto-injectors, or their authorized generics label. As stated on the product label, consumers should always seek emergency medical help right away after using their epinephrine auto-injector.
FDA asks health care professionals and consumers to report any adverse reactions or quality problems to the FDA’s MedWatch program:
Click here for the press release.
Click here for the letter from Pfizer.